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Research Article
Transcriptional Profiling of theMouse Hippocampus
Supports an NMDAR-Mediated Neurotoxic
Mode of Action for Benzo[a]Pyrene
Nikolai L.Chepelev,1Alexandra S. Long,1Wayne J. Bowers,1Remi Gagne,1
Andrew Williams,1Byron Kuo,1David H. Phillips,2 Volker M. Arlt,2
Paul A.White,1and Carole L.Yauk1*
1Environmental Health Science and Research Bureau, Environmental and Radia-
tion Health Sciences Directorate, HECSB, Health Canada, Ottawa, Ontario,
Canada K1A 0K9
2Analytical and Environmental Sciences Division, MRC-PHE Centre for Environ-
ment and Health, King’s College London, London, SE1 9NH, United Kingdom
Benzo[a]pyrene (BaP) is a genotoxic carcinogen
and a neurotoxicant. The neurotoxicity of BaP is
proposed to arise from either genotoxicity lead-
ing to neuronal cell death, or perturbed expres-
sion of N-methyl-D-aspartate receptor (NMDAR)
subunits. To explore these hypotheses, we pro-
filed hippocampal gene expression of adult
male Muta
TM
Mouse administered 0, 1, 35, or
70 mg BaP/kg bw per day by oral gavage for
3 days. Transcriptional profiles were examined
by RNA-sequencing (RNA-seq), DNA microar-
rays, and real-time quantitative reverse transcrip-
tion polymerase chain reaction (RT-PCR). BaP-
DNA adducts in the cerebellum were quantified
by 32P-post-labeling to measure genotoxicity.
RNA-seq revealed altered expression of 0, 260,
and 219 genes (P-value<0.05, fold-change6
1.5) following exposure to the low, medium,
and high doses, respectively; 54 genes were
confirmed by microarrays. Microarray and RT-
PCR analysis showed increased expression of
NMDAR subunits Grina and Grin2a. In con-
trast, no effects on DNA-damage response
genes were observed despite comparable BaP-
DNA adduct levels in the cerebellum and in the
lungs and livers of mice at similar BaP doses in
previous studies. The results suggest that DNA-
damage response does not play a major role
in BaP-induced adult neurotoxicity. Meta-analysis
revealed that BaP-induced transcriptional profiles
are highly correlated with those from the hippo-
campus of transgenic mice exhibiting similar
neurotoxicity outcomes to BaP-exposed mice
and rats (i.e., defects in learning and memory).
Overall, we suggest that BaP-induced neurotox-
icity is more likely to be a consequence of
NMDAR perturbation than genotoxicity, and
identify other important genes potentially media-
ting this adverse outcome. VC 2016 Her Majesty
the Queen in Right of Canada. Environmenta-
l and Molecular Mutagenesis VC 2016 Environmental
Mutagen Society.
Key words: toxicogenomics; human health risk assessment; mode of action; learning and memory;
glutamate receptor
INTRODUCTION
Benzo[a]pyrene (BaP)1 is a human carcinogen that
operates through a genotoxic mode of action (MOA)
[IARC, International Agency for Research on Cancer,
2010]. In addition to causing tumors at multiple sites in
rodent cancer bioassays, rodents exposed to BaP exhibit
poor performance in behavioral tests, suggesting that
BaP retards learning and memory in laboratory animals
(reviewed in [Chepelev et al., 2015]). For example,
oral exposure of neonate pups to BaP for six days leads
to a significant decrease in Morris water maze test
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performance measured 63 days after the last exposure
[Chen et al., 2012].
Laboratory animals exposed to BaP in utero, postna-
tally, and during adulthood exhibit neurotoxicity at doses
below those inducing carcinogenicity (reviewed by [Mof-
fat et al., 2015]). Benchmark dose (BMD) modeling of
neurotoxicity and carcinogenicity in rodent experiments
supports this [Chepelev et al., 2015]. In addition, several
epidemiological studies have revealed potential neuro-
toxic effects of BaP (as a part of ambient mixtures of pol-
ycyclic aromatic hydrocarbons [PAHs]) in humans. For
example, exposure to PAH mixtures was associated with
a drop in IQ of up to 4.9 points in children 5 years of
age [Perera et al., 2009]. A drop in IQ of similar magni-
tude to that observed following BaP exposure in PAH
mixtures is also elicited by other well-characterized neu-
rotoxicants. For instance, an IQ drop of 1–3 is associated
with exposure to arsenic in 5-year-old girls [Hamadani
et al., 2011]. In addition, there is an association between
“PAH-like” DNA adducts in children and adverse cogni-
tive/behavioral development [Perera et al., 2011; Perera
et al., 2015]. Given these observed neurotoxic effects of
BaP at low doses, and their apparent human relevance,
the mechanisms underlying BaP neurotoxicity in both
developing and adult exposure scenarios merit further
investigation.
A detailed review of 40 published studies on BaP-
induced neurotoxicity [Chepelev et al., 2015] suggested
that the most well-supported MOA to explain the neuro-
toxicity of BaP involves the following sequential key
events: (1) BaP binding to the aryl hydrocarbon receptor
(AHR); (2) altered transcription of N-methyl-D-aspartate
glutamate receptor (NMDAR) subunits due to AHR acti-
vation; (3) NMDAR-mediated decreases in neuronal
activity and long-term potentiation; and (4) compromised
learning and memory (Fig. 1). Although the specific
underlying mechanisms of BaP neurotoxicity may be dif-
ferent in developing animals and adults, perturbed
NMDAR expression has been reported in both postnatal
[Brown et al., 2007; Patri et al., 2013] and adult mice
and rats [Grova et al., 2007; Grova et al., 2008; Qiu
et al., 2011; Cheng et al., 2013], and even in rat cortical
neurons [Brown et al., 2007] and neuroblastoma Neuro2a
cells [Patri et al., 2013] following BaP exposure. Thus,
this proposed MOA may be relevant to both adult and in
utero/postnatal exposure to BaP.
NMDARs are heterotetramers composed of two obliga-
tory glycine-binding NR1, or Grin1 (Glutamate receptor,
ionotropic, N-methyl D-aspartate 1) subunits, and regula-
tory glutamate-binding NR2 (Grin2) and/or NR3 (Grin3)
subunits [Stephenson, 2006]. Alterations in NMDAR sub-
unit expression have significant effects on learning and
memory in mice and rats. Specifically, conditional knock-
out of NR1 in mouse hippocampus, the site where the
conversion of short-term to long-term memories takes
place, leads to impaired ability to learn the location of
the hidden platform in the Morris water maze test
[Shimizu et al., 2000]. In contrast, overexpression of
NR2B subunits in the mouse forebrain increases the dura-
tion of the NMDAR currents and significantly improves
the performance of mice in various behavioral tasks
[Tang et al., 2001]. The importance of NMDARs in main-
taining functional learning and memory in rodents has
prompted researchers to examine NMDAR gene expres-
sion during BaP-induced neurotoxicity in rats and mice
[Brown et al., 2007; Grova et al., 2007; Grova et al.,
2008; Qiu et al., 2011; Cheng et al., 2013].
In addition to NMDAR-mediated neurotoxicity, an
intriguing hypothesis has emerged that genotoxic com-
pounds may cause both carcinogenicity and neurotoxicity,
depending upon the presence (e.g., hepatocytes) or
absence (e.g., post-mitotic neurons) of active cell division
[Kisby et al., 2011]. A good example of such a compound
is methylazoxymethanol (MAM). MAM reduces cell via-
bility in the cerebellar granule neurons [Kisby et al.,
2009], most likely as a result of DNA damage (reviewed
in [Kisby et al., 2013]). MAM causes both colon cancer
and neurotoxicity, and perturbs similar cellular signaling
pathways in these tissues [Kisby et al., 2011]. The three
pathways that are shared between MAM-induced colon
cancer and neurological diseases are the transforming
growth factor-beta (TGF-beta) pathway, the wingless and
proto-oncogene Int-1 (Wnt) pathway, and mitogen-
activated protein kinase (MAPK) signaling pathways
[Kisby et al., 2011]. Whether these pathways or other
downstream consequences of BaP genotoxicity in the
brain are shared between cancer and neurotoxicity rodent
models in general, and between BaP-mediated carcinoge-
nicity and neurotoxicity in particular, is unknown.
We have extensively investigated the mutagenic effects
of acute and subchronic (i.e., 3- or 28-day) oral exposure
to BaP in several tissues of adult Muta
TM
Mouse transgenic
rodents (e.g., [Moffat et al., 2015; Long et al., 2016; Mof-
fat et al., 2015]). Since BaP is a well-recognized muta-
genic carcinogen, the results showed expected
perturbations in the genes involved in the p53-mediated
DNA damage response pathway, including cyclin-
dependent kinase inhibitor 1A (Cdkn1a), following acute
exposures that are anchored to measured genotoxic effects
(reviewed in [Moffat et al., 2015]). Therefore, it is rea-
sonable to speculate that cytotoxic and genotoxic effects
of BaP on the hippocampus contribute to the observed
neurotoxic effects. Transcriptomics studies can be applied
to evaluate this hypothesis as an alternative MOA for
BaP neurotoxicity (Fig. 1), and our previous work sup-
ports that transcriptional changes are measurable indica-
tors of genotoxicity.
In the present study we examined global hippocampal
transcriptional profiles of adult MutaTMMouse males
acutely exposed to BaP in order to: (1) test the hypothesis
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that the neurotoxic effects of BaP in adult rodents are
predominantly manifested via the modulation of NMDAR
expression (i.e., versus DNA damage response leading to
increased neuronal cell death); (2) identify potentially
shared signaling pathways for BaP-induced genotoxicity
and neurotoxicity; and (3) explore other plausible MOAs
or modulating factors involved in BaP-induced
neurotoxicity.
MATERIALS ANDMETHODS
Animal Treatment
Adult MutaTMMouse (strain 40.6, 9 weeks of age) males were indi-
vidually housed in a microVENT ventilated rack (Allentown Inc., Allen-
town, NJ) on a 12 hr light/12 hr dark cycle. MutaTMMouse was used in
this project due to the established expertise of our group in the use of
this model system while studying BaP mutagenicity. Mice received
standard rodent chow (2014 Teklad Global standard rodent diet) ad libi-
tum for the duration of the study. Animals were administered BaP (CAS
no. 50-32-8, purity 98%, Cambridge Isotopes, Tewksbury, MA) dis-
solved in highly refined olive oil (Sigma-Aldrich, Oakville, ON, Canada)
delivered at 0.005 ml/g body weight. BaP (0, 1, 35, and 70 mg/kg bw
per day) was administered by oral gavage for three consecutive days.
Doses were selected based on a previous study [Chen et al., 2012] that
we determined to be the most suitable for health risk assessment [Chepe-
lev et al., 2015] and that used the relevant route of exposure (i.e., oral
gavage). This study described significant effects on Morris water maze
test performance in rats dosed postnatally (days 5-11) with 0.2 and
2 mg/kg bw per day by oral gavage for six days (effects observed up to
63 days after the last exposure) [Chen et al., 2012]. Because we are
using an adult model, we increased the lowest dose showing neurotoxic-
ity in Chen et al. (i.e., 0.2 mg/kg bw per day) to 1.0 mg/kg bw per day
to compensate for the anticipated lower susceptibility of the adult brain
to BaP. We chose to focus on adult rather than developmental exposure
because of the numerous adult studies demonstrating BaP-induced neuro-
toxicity (e.g., [Grova et al., 2007; Grova et al., 2008; Qiu et al., 2011;
Cheng et al., 2013]) and for comparison with our previous global gene
expression analyses in MutaTMMouse lung [Halappanavar et al., 2011]
and liver [Moffat et al., 2015] following 3-day exposures to BaP, where
we characterized extensive evidence of DNA damage response in the
transcriptome.
There were five animals in each dose group, as well as in the vehicle
control group. After 24 hr, animals were anesthetized with isoflurane gas
and then euthanized by cardiac puncture, followed by cervical disloca-
tion and chest cavity opening. This time interval was chosen based on a
previous study showing that administration of radiolabeled BaP leads
to a peak of radioactivity in the brain at 23 hr [Das et al., 1985]. The
Fig. 1. Proposed mode of action (MOA) for BaP-induced neurotoxicity
in rodents (reviewed in and redrawn from [Chepelev et al., 2015]). The
MOA for BaP neurotoxicity in rodents is hypothesized to proceed though
the altered expression of N-methyl D-aspartate receptors (NMDARs) that
are heterotetramers of two obligatory glycine-binding NR1 (a.k.a. Gluta-
mate receptor, ionotropic, N-methyl D-aspartate 1 or Grin1) subunits and
regulatory glutamate-binding NR2 (Grin2) and/or NR3 (Grin3) subunits.
The altered expression of NMDARs in response to BaP has been shown
in several studies [Brown et al., 2007; Grova et al., 2007; Grova et al.,
2008; Qiu et al., 2011; Cheng et al., 2013] and could be due to transcrip-
tional regulation of xenobiotic response element- (XRE-) containing genes
(e.g., Grin2a) by aryl hydrocarbon receptor (AHR), following its binding
to BaP, nuclear translocation, and heterodimerization with AHR nuclear
translocator (Arnt). Altered hippocampal expression of NMDAR may alter
the magnitude of NMDAR-mediated ion currents, resulting in reduced
long-term potentiation (LTP) and, hence, impaired learning and memory.
An alternative MOA involves the genotoxicity of BaP metabolites, which
could lead to neuronal death and presumably similar behavioral outcome.
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whole brain was removed, and the hippocampus and cerebellum sepa-
rated. Tissues were flash-frozen in liquid nitrogen and stored at –808C.
Mice were bred, maintained, and treated in accordance with the Cana-
dian Council for Animal Care Guidelines. Animal care and handling
were approved by Health Canada’s Animal Care Committee.
DNA Adduct Analysis
While aligning transcriptomic and DNA adduct data would be of
great relevance to this study, the small amount of DNA recoverable
from the mouse hippocampus (i.e., the tissue that would be the most rel-
evant to learning and memory impairments induced by neurotoxicants)
precluded DNA adduct analysis in this target tissue. Therefore, cerebel-
lum was used as a surrogate tissue for hippocampus. Approximately half
of the entire cerebellum (one hemisphere chosen randomly) was minced
and combined with 5-ml ice cold lysis buffer (1 mM Na2EDTA,
100 mM NaCl, 20 mM Tris-HCl, pH 7.4) supplemented with 1% SDS
(w/v) and 0.1 mg/ml RNase A, and incubated at 37˚C overnight with
gentle shaking. Genomic DNA was isolated using a phenol/chloroform
extraction procedure described previously [Douglas et al., 1994; Vijg
and Douglas, 1996]. Isolated DNA was dissolved in 100 ml TE buffer
(10 mM Tris pH 7.6, 1 mM EDTA) and stored at 4˚C until use.
DNA adducts were measured for each DNA sample using the 32P-
post-labeling method using the nuclease P1 digestion enrichment version
of the assay [Phillips and Arlt, 2014]. For analysis, DNA samples (4 mg)
were digested with micrococcal nuclease (288 mUnits) and spleen phos-
phodiesterase (1.2 mUnits), enriched, and labeled as reported elsewhere
[Phillips and Arlt, 2014; Arlt et al., 2015; Krais et al., 2016]. Chromato-
graphic conditions for thin-layer chromatography (TLC) on
polyethyleneimine-cellulose (PEI-cellulose) plates (Macherey-Nagel,
D€uren, Germany) were: D1, 1.0 M sodium phosphate, pH 6; D2, 4 M
lithium-formate, 7 M urea, pH 3.5; and D3, 0.8 M lithium chloride,
0.5 M Tris, 8.5 M urea, pH 8. After chromatography, TLC sheets were
scanned using a Packard Instant Imager (Dowers Grove, IL), and DNA
adduct levels (RAL, relative adduct labeling) were calculated from
adduct cpm, the specific activity of [g-32P]ATP, and the amount of
DNA (pmol of DNA-P) used. An external BaP-7,8-dihydro-diol-9,10-
epoxide (BPDE)-DNA standard was used for identification of BaP-DNA
adducts as described [Arlt et al., 2008; Krais et al., 2016]. Results are
expressed as DNA adducts/108 nucleotides.
Global Transcriptional Profiling
RNA was isolated, hybridized, and analyzed as previously described
[Malik et al., 2013; Jackson et al., 2014]. For RNA-sequencing, 4 mg of
RNA with RNA integrity numbers above 7.0 per sample (Agilent 2100
Bioanalyzer) was shipped on dry ice to the McGill University and
Genome Quebec Innovation Centre (Montreal, Canada), where cDNA
libraries were built following the polyA-enrichment Illumina TruSeq v2
protocol. Hippocampi sample cDNA libraries were then ligated to Illu-
mina adapters and paired-end sequenced on a HiSeq2000 with N5 5 for
control, N5 4 for low, medium, and high doses. Sequencing was per-
formed at the McGill University and Genome Quebec Innovation Centre
(Montreal, Canada). The sequencing depth was 40 million reads and the
read length was 100 base pairs.
Data processing was carried out with Illumina’s Real Time Analysis
software, and converted into FASTQ files using Illumina’s CASAVA
software. The GRCm38 mouse genome was used to align the FASTQ
files with STAR’s default parameters [Dobin et al., 2013]. Feature
counting of the Ensembl Gene Set (GRCm38v75) was performed in
Python using HTSeq-count (version 0.6.1) [Anders et al., 2015]; the m
parameter was set to “intersection-nonempty.” The EdgeR [Robinson
et al., 2010] and TMM normalization [Robinson and Oshlack, 2010]
were used to calculate differentially expressed genes using the exactTest
function, producing gene lists with fold-change with respect to controls
and the corresponding false-discovery rate- (FDR) adjusted p-values.
The complete dataset is available through the Sequence Read Archive
(SRA) at http://www.ncbi.nlm.nih.gov/sra, project number
PRJNA304295.
For microarray analysis, cDNA and cyanine-labeled cRNA were syn-
thesized (Agilent Linear Amplification Kit) from 250 ng of total RNA
from sample and universal mouse reference total RNA (Stratagene, Can-
ada). Samples were in vitro transcribed and hybridized using a two-color
reference design as described previously [Labib et al., 2012] to Agilent
8x60 K whole genome microarrays. Arrays were scanned on an Agilent
G2505B scanner and data acquired using Agilent Feature Extraction
Software, version 11. Normalization was performed using locally
weighted scatterplot smoothing (LOWESS) [Yang et al., 2002] in R [R-
Development-Core-Team, 2010]. The determination of differential gene
expression was carried out by microarray analysis of variance (MAA-
NOVA) [Wu et al., 2003], and the false-discovery rate- (FDR) adjusted
p-values were calculated as described elsewhere [Jackson et al., 2014].
The complete dataset is available from GEO (accession number
GSE75206).
Real-Time Quantitative Reverse Transcription Polymerase
Chain Reaction (RT-PCR) Validation
A custom RT-PCR array containing proprietary probes (Qiagen) was
designed to measure the expression of certain NMDARs that were dif-
ferentially expressed in previous studies in response to BaP in the brain,
to test our hypothesis of the involvement of NMDARs in mediating BaP
neurotoxicity, as well as to validate the RNA-seq and microarray data.
Therefore, the arrays measured the expression of Grin1, Grin2a, and
Grin2b (at least one of these genes was affected in previous studies
[Grova et al., 2007; Grova et al., 2008; Qiu et al., 2011; Cheng et al.,
2013]), other NMDAR genes (Grina and Grin3a), and some genes iden-
tified as differentially expressed by our RNA-seq and/or microarray anal-
ysis: claudins 2 and 5 (Cldn2 and Cldn5), ephrin type-A receptor 7
(Epha7), hypoxia-inducible factor 3A (Hif3a), 3-hydroxy-3-
methylglutaryl-CoA synthase 2 (Hmgcs2), perilipin 4 (Plin4),
semaphorin-3B (Sema3b), and semaphorin-5A (Sema5a). In addition, the
arrays contained Glucuronidase beta (Gusb) to act as housekeeping gene
for normalization as in previous work [Labib et al., 2012], and mouse
cDNA genomic contamination control and reverse transcription control
reactions. Total RNA that isolated from the hippocampus during sample
preparation for RNA-seq and microarray analyses was used. RT2 Easy
First Strand Kits (Qiagen) were used to generate cDNA libraries from
0.5 micrograms of total RNA, in accordance with the manufacturer’s
protocol. Arrays were run on a CFX96 real-time detection system (Bio-
Rad). Ct values were normalized to Gusb and gene expression was ana-
lysed at http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php.
Bionformatic Analyses
All genes with FDR P 0.05 and fold change6 1.5 relative to
controls were analysed to identify biological pathways, functions, or
processes that are affected in the hippocampus following BaP exposure
by Ingenuity Pathway AnalysisTM (IPATM, Ingenuity Systems, Redwood
City, CA) and NextBioTM (http://nextbio.com). Fisher’s exact tests were
used in IPA to examine the significance of the association between a
given dataset and IPA-defined canonical pathways and functions. Next-
BioTM was used to compare a given dataset to their library of curated
datasets to identify studies with similar gene expression profiles using
the meta-analysis function. The significance of negative or positive cor-
relations between datasets is assessed in NextBioTM by considering a
number of factors, most notably, directionality and the strength of the
overlap/enrichment between a pair of datasets [Kupershmidt et al.,
2010].
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Statistical Analyses
The DNA adduct data were analysed using SAS software, Version
9.1 of the SAS System for Windows (VC 2013 SAS Institute Inc, Cary,
NC) by Poisson regression. The data were fitted to the model
log(E(Yi))5 log ti1bxi, where E(Yi) is the expected value for the ith
observation, b is the vector of regressions coefficients, xi is a vector of
covariates for the ith observation, and ti is the offset variable used to
account for differences in observation count period. The offset was
given a constant coefficient of 1.0 for each observation, and log-linear
relationships between adduct frequency and test article concentration
were specified by a natural log link function. Type 1, or sequential anal-
ysis, was employed to examine the statistical significance of the chemi-
cal treatment. Body weights were analysed by the “ANOVA” (one-way
analysis of variance) function in Microsoft Excel.
Benchmark Dose (BMD)Modeling
For RNA-seq data, normalized log2-transformed expression values
for individual genes were fit as continuous data to a series of four dose-
response models (Hill, power, linear, and second degree polynomial) by
BMDExpress software [Yang et al., 2007]. Each model was run assum-
ing constant variance, with maximum iterations of 250, benchmark
response (BMR) factor of 1.349, confidence level of 0.95, and power
restricted to 1. For the Hill model, if the k parameter was less than 1/3
of the lowest dose, the output was flagged, and the next best fit model
was selected if it had a goodness-of-fit P-value> 0.05. The probes were
filtered (ANOVA P-value 0.05) prior to the analysis, as described else-
where [Webster et al., 2015], and BMD analysis was performed only on
differentially expressed probes.
RESULTS
General Response of MutaTMMouse to BaP
Mice treated with 1, 35, or 70 mg/kg bw BaP per day
for 3 days displayed neither overt signs of toxicity, nor
body weight loss relative to controls (data not shown).
Serum biochemistry tests revealed increases in lipase and
decreases in magnesium at all of the doses compared to
controls, and an increase in creatinine at the medium
dose (Supporting Information Fig. 1).
DNA Adducts in the Cerebellum
Analysis of cerebellar DNA showed dose-dependent
increases in BaP-DNA adducts, with significant increases
in adduct levels at all concentrations relative to control
(Fig. 2A). The DNA adduct pattern observed by TLC
32P-post-labeling in BaP-treated mice consisted of a sin-
gle adduct spot that was previously identified by mass
spectrometry as 10-(deoxyguanosin-N2-yl)27,8,9-trihy-
droxy-7,8,9,10-tetrahydro-BaP (dG-N2-BPDE) [Arlt et al.,
2008] (Fig. 2B). No adduct formation was detected in
cerebellar DNA isolated from untreated mice (data not
shown). The highest adduct level detected was
64.26 17.6 adducts per 108 nucleotides at the highest
dose (Fig. 2).
We compared our findings to adduct data from lung
and liver samples in a previous study on MutaTMMouse
males treated with 0, 5, 50, 150, and 300 mg/kg bw BaP
per day for 3 days [Halappanavar et al., 2011]. These
authors also noted a dose-dependent increase in the levels
of adducts in the lungs and livers of exposed animals.
Interpolation from this dose-response curve suggests that
the BaP-DNA adduct levels in MutaTMMouse lung and
liver at 70 mg/kg bw per day exposure would be
1.82 3.2 times higher than the adduct levels observed at
this exposure level in the cerebellum in this study. How-
ever, the interpolated value for the liver measured 24 h
following BaP exposure is 116.56 72.8 adducts per 108
nucleotides, which overlaps with the cerebellum adduct
Fig. 2. Dose-dependent formation of BaP-DNA adducts detected in the
cerebellum of MutaTMMouse by 32P-post-labeling. A: Error bars represent
standard error of the mean of four to five mice (each DNA sample ana-
lyzed in two independent post-labeling assays). Asterisks (*) denote statis-
tically significant differences from control at the P< 0.0001 level. B:
Representative autoradiographic adduct profile obtained by 32P-post-label-
ing in the cerebellum of MutaTMMouse dosed with BaP. The major spot
shows 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydro-BaP
(dG-N2-BPDE). The origin (OR), at the bottom left-hand corner, was cut
off before exposure. D2 and D3 indicate the solvent conditions used on
the TLC (see Materials and Methods).
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level of 64.26 17.6 adducts per 108 nucleotides from this
study at 70 mg/kg bw per day (Fig. 3).
Gene Expression Changes in the Hippocampus by RNA-
Sequencing
BaP did not affect gene expression at the lowest dose,
but altered the expression of 230 and 212 genes (FDR
P 0.05 and fold change6 1.5) at the medium and
high doses, respectively, 24 hr after the last treatment
(Fig. 4 and Supporting Information Table 1). Planar cell
polarity (PCP) was the top IPA pathway affected at the
medium dose of BaP in the hippocampus. Six out of 63
genes that belong to this signaling pathway were downre-
gulated and the pathway was predicted to be inhibited by
the treatment (Z-score of 22.4). “Neurological disease”
was the top “diseases and disorders” category at the
medium dose, with 26 genes associated with this category
perturbed by BaP treatment. Transcript changes for the
high dose of BaP were significantly enriched in genes
under the control of estrogen receptor 1 (ESR1), the top
upstream regulator in this dataset. The expression of 22
out of 30 ESR1-regulated genes affected in this study was
consistent with ESR1 activation (Z-score of 3.5). In con-
trast, there was no single prominent upstream regulator
identified in the genes that were altered at the medium
dose. “Phospholipases” was the top IPA canonical path-
way affected by the high BaP dose, reflecting the down-
regulation of endothelial lipase (Lipg) and upregulation of
three phospholipases A2 (Plag3, Plag4e, and Plag5).
Cancer was the most enriched category under “diseases
and disorders” at the high dose, with a total of 179 mole-
cules from that category perturbed.
Gene Expression Changes in the Hippocampus by DNA
Microarrays
Microarray analysis revealed 259 differentially expressed
transcripts (FDR P 0.05 and fold change6 1.5) in the
hippocampus following administration of the high dose of
BaP relative to control mice (Supporting Information Table
2). Based on gene symbol, 52 of these genes were also iden-
tified as differentially expressed by RNA-seq at the high
dose (Supporting Information Table 3). As in the RNA-seq
IPA analysis, the results suggest that ESR1 was the top
upstream regulator of differentially expressed genes. The
top network for the shared gene set was “behavior, develop-
mental disorder, and hereditary disorder”. The top affected
IPA canonical pathway was “Axonal guidance signaling”,
encompassing 12 genes including Fzd4, Wnt3, and Wnt4.
These three genes are also part of the PCP pathway that
was identified as perturbed in the RNA-seq analysis of the
medium and high doses.
Meta-Analysis to Identify Diseases and Treatments with Similar
Transcript Pro¢les in NextBio
Query of the BaP-exposed mouse hippocampal gene
expression profiles (both RNA-seq and microarray results)
Fig. 3. Dose-response comparison of BaP-DNA adduct levels detected
by 32P-postlabeling in lung, liver ([Halappanavar et al., 2011] and unpub-
lished data), and cerebellum (this study) in MutaTMMouse dosed with
BaP for three consecutive days by oral gavage. Plotted values are
means6 standard deviation (n5 8). Estimated adduct levels for lung and
liver at the high dose used in this study (i.e., 70 mg BaP/kg bw per day)
are shown in the table. Estimates are based on linear trends (i.e., slopes
of dose-response function)6 standard error of the interpolated values that
were calculated from the mean values plotted here.
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against the studies curated in NextBio revealed the most
similar profiles were from the hippocampus of C57Bl/6
mice harboring postnatal, neuron-specific ablation of
Euchromatic Histone-lysine N-Methyltransferase 1 (also
known as G9a Like Protein or GLP) compared to wild-
type mice [Schaefer et al., 2009]. A comparison between
profiles of mice with GLP ablation [Schaefer et al., 2009]
and profiles from our study is shown in Figure 5. There
were 79 genes in common between the two datasets (Fig.
5C; Supporting Information Table 4); of these, 72 were
upregulated in both studies (Fig. 5D). The results are
again consistent with activation of ESR1, which is sup-
ported by increased expression in both datasets in 15 of
these 72 genes. In addition, the analysis revealed that
BaP-induced hippocampal gene expression shares much
stronger similarity to compounds with “unclassified
toxicity” (250 studies; the top similar category) than other
toxicity types including “mutagens” (11 studies; the 19th
similar category). The “mutagens” category included
three BaP studies in MutaTMMouse lung and liver [Halap-
panavar et al., 2011], rat primary hepatocytes [Doktorova
et al., 2013], and mouse hepatoma Hepa-1c1c7 cells
[Ovesen et al., 2014].
Validation of Gene Expression Changes by RT-PCR
Twelve genes were selected for additional analysis by
RT-PCR. We purposefully selected genes that have previ-
ously been documented to be affected in the hippocampus
following BaP exposure, albeit by different routes of
exposure (gestational exposure [Brown et al., 2007] or
intraperitoneal injection [Grova et al., 2007; Grova et al.,
2008; Qiu et al., 2011; Cheng et al., 2013]). Most nota-
bly, the expression of NMDAR subunits including Grin1,
Grin2a, and Grin2b, and the related genes Grina and
Grin3a were examined. Finally, a selection of other genes
identified in the RNA-seq and microarray analysis were
also included: Cldn2 and Cldn5, ephrin type-A receptor 7
(Epha7), hypoxia-inducible factor 3A (Hif3a), 3-hydroxy-
3-methylglutaryl-CoA synthase 2 (Hmgcs2), perilipin 4
(Plin4), semaphorin-3B (Sema3b), and semaphorin-5A
Fig. 4. Venn diagram showing the number of genes in the hippocampus
of BaP-exposed Muta
TM
Mouse that were differentially expressed (false-
discovery rate-adjusted P-values 0.05 and fold change6 1.5 relative
to control) using RNA-seq and Agilent microarrays.
Fig. 5. Identification of the most similar toxicogenomics study in Next-
Bio. The gene expression profiles from the 70 mg/kg bw per day dose
measured by RNA-seq (bioset 1) compared with concurrent solvent con-
trols was queried against the NextBio database. The analysis revealed that
hippocampal gene expression from a GLP knock-out study in mouse
([Schaefer et al., 2009], bioset 2) shared the greatest overlap with the
BaP dataset. A, B: Characterization of each bioset. C: Number of genes
that were differentially expressed in both data sets (false-discovery rate-
adjusted P-values 0.05 and fold change6 1.5). D: Statistical signifi-
cance of the overlap between the four gene subsets, determined by Next-
Bio. We note that Next-Bio and IPA count the number of differentially
expressed genes differently; hence, the number of differentially expressed
genes reported here is 216 vs. 212 in Fig. 4.
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(Sema5a). As Table I illustrates, no significant changes in
the expression of any of these genes were observed using
RT-PCR for the low and medium doses. At the high
dose, significant alterations occurred in the expression of
six of the 12 genes (Table I) in BaP-exposed relative to
control mice. The expression of nine of the 12 genes
examined by RT-PCR was consistent across at least two
technologies (Table I). In addition, the direction of
change for affected genes was consistent, and the magni-
tude of change varied less than two-fold, across all
technologies.
Our RT-PCR analysis did not examine changes in the
expression of genes commonly associated with a DNA
damage response. Therefore, another PCR array was used
to measure the changes in the expression of genes that
are directly or indirectly associated with BaP-induced
DNA damage and DNA damage response, such as the
p53-mediated DNA damage response gene cyclin-
dependent kinase inhibitor 1A (Cdkn1a), and other known
BaP-inducible genes such as NAD(P) quinone oxidoredu-
case 1 (Nqo1), cytochrome P450 1a1 (Cyp1a1), and cyto-
chrome P450 1b1 (Cyp1b1). Previous work showed that
hepatic expression of these genes was significantly altered
by BaP exposure four and/or 24 hr following a three-day
repeat dose exposure to 5, 50, 150, or 300 mg/kg bw
[Moffat et al., 2015] (see Cyp1a1 summary in Supporting
Information Fig. 2). Despite the fact that the aforemen-
tioned experiment covered the range of BaP doses used
in this study (i.e., 5-300 vs. 1-70 mg/kg bw per day), our
RT-PCR array analysis did not reveal significant changes
in any of these genes in the hippocampus of BaP-treated
mice relative to controls (Supporting Information Table
5). However, we note that some genes involved in xeno-
biotic metabolism of BaP that were not on our PCR
arrays were identified in the BMD analysis described
below.
Benchmark Dose (BMD) Analysis of Transcriptional Changes
The genomics data generated here were used for dose-
response modeling and BMD determination, as was con-
ducted for other tissues from BaP-exposed animals exam-
ined previously [Moffat et al., 2015]. To this end, the
dose-response data for all 387 mouse IPA pathways were
modelled using BMDExpress. First, we identified 11 IPA
pathways containing Grin1, Grin2a, Grin2b, Grin2c,
Grin2d, Grina, and Grin3a (Supporting Information Table
6), and investigated median BMD values for these path-
ways. We also identified the ten “most sensitive” path-
ways (i.e., those with the lowest median BMDLs)
(Supporting Information Table 7). This analysis identified
that three out of the 11 IPA pathways that include the
Grin proteins (Amyotrophic Lateral Sclerosis Signaling,
Synaptic Long Term Potentiation, and Huntington’s Dis-
ease Signaling) were also among the ten most sensitive
pathways (Supporting Information Table 7). The most
sensitive pathways were “Synaptic Long Term
Potentiation” and “G-Protein Coupled Receptor Signal-
ing”, both yielding median BMDL values of 5.2 mg/kg
bw per day. Other IPA pathways with low BMDLs
included “Xenobiotic Metabolism Signaling” and “Nrf2-
mediated Oxidative Stress Response” (Supporting Infor-
mation Table 7). These two pathways include several
genes involved in BaP metabolism. For example, the
expression of epoxide hydrolase 1 (Ephx1) and aldehyde
oxidase 1 (Aox1) was increased by 1.7- and 1.6-fold,
respectively, at the high dose, and glutathione S-transfer-
ase mu 2 (Gstm2) was increased by 2.4-fold at the
medium dose. These two IPA pathways were also
affected in the lungs and livers of BaP-treated mice, and
were considered as a part of a toxicogenomics-based car-
cinogenic MOA developed for BaP [Moffat et al., 2015].
Consistent with the lack of BaP effect on DNA damage-
inducible genes, the IPA pathways that were used in
deriving toxicogenomic PODs for mouse liver, lung, and
forestomach (so selected because of their relationship to
the key event “DNA adducts and DNA damage” in the
carcinogenic MOA for BaP developed previously [Moffat
et al., 2015]), were either unaffected (Supporting Informa-
tion Fig. 3) or contained only 2 or 3 affected genes per
pathway (data not shown).
DISCUSSION
Measurement of genome-wide transcriptomic responses
to BaP permits an unbiased evaluation of potential MOAs
and modulating factors involved in its neurotoxicity in
adult rodents. Our study confirms expression changes in
NMDARs and suggests that ESR1 activation occurs fol-
lowing BaP exposure, which may be involved in the
learning and memory processes that are regulated by GLP
in the brain. Our analyses do not support extensive DNA
damage responses or alterations in cell cycle (typical tran-
scriptional consequences of genotoxicity) in the hippo-
campal tissue.
Prior to whole-genome profiling we measured BaP-
DNA adduct formation in order to gain insight into the
distribution of BaP and/or its metabolites in the brains of
treated animals. Cerebellum was used as a surrogate
region for adduct analyses due to the prohibitively small
size of the murine hippocampus. Metabolised BaP did
reach the brain, as indicated by the presence of dG-N2-
BPDE adducts measured by 32P-post-labeling (Fig. 2).
This result is consistent with a previous report of
increased levels of BaP-DNA adducts in rat cortex fol-
lowing one-, two-, or three-month exposures to BaP by
intraperitoneal injection [Nie et al., 2013]. However, the
magnitude of the cerebellar DNA damage observed in
this study was 2-3 times lower than that previously
Environmental and Molecular Mutagenesis. DOI 10.1002/em
8 Chepelev et al.
TA
BL
E
I.
T
h
e
E
xp
re
ss
io
n
of
S
el
ec
te
d
G
en
es
M
ea
su
re
d
b
y
R
N
A
-s
eq
u
en
ci
n
g
(R
N
A
-s
eq
),
A
gi
le
n
t
M
ic
ro
ar
ra
ys
,
an
d
R
T
-P
C
R
,
in
th
e
H
ip
p
oc
am
p
u
s
of
M
u
ta
T
M
M
ou
se
24
h
r
F
ol
lo
w
in
g
th
e
E
xp
os
u
re
to
B
aP
fo
r
3
D
ay
s
A
cc
es
si
o
n
n
u
m
b
er
G
en
e
S
y
m
b
o
l
G
en
e
N
am
e
R
N
A
-s
eq
R
T
-P
C
R
M
ic
ro
ar
ra
ys
3
5
.0
m
g
/k
g
b
w
p
er
d
ay
7
0
.0
m
g
/k
g
b
w
p
er
d
ay
3
5
.0
m
g
/k
g
b
w
p
er
d
ay
7
0
.0
m
g
/k
g
b
w
p
er
d
ay
7
0
.0
m
g
/k
g
b
w
p
er
d
ay
F
o
ld
ch
an
g
e
F
D
R
p
-v
al
u
e
F
o
ld
ch
an
g
e
F
D
R
p
-v
al
u
e
F
o
ld
ch
an
g
e
F
D
R
p
-v
al
u
e
F
o
ld
ch
an
g
e
F
D
R
p
-v
al
u
e
F
o
ld
ch
an
g
e
F
D
R
p
-v
al
u
e
N
M
_
0
0
8
1
7
0
G
ri
n
2
a
G
lu
ta
m
at
e
re
ce
p
to
r,
io
n
o
tr
o
p
ic
,
N
M
D
A
2
A
(e
p
si
lo
n
1
)
2
1
.6
0
0
.3
2
9
1
.2
2
0
.7
6
3
1
.2
2
0
.6
0
9
2.
20
0.
02
6
1.
63
0.
00
0
N
M
_
0
0
8
1
6
9
G
ri
n
1
G
lu
ta
m
at
e
re
ce
p
to
r,
io
n
o
tr
o
p
ic
,
N
M
D
A
1
(z
et
a
1
)
2
1
.0
4
0
.9
3
2
1
.0
9
0
.7
4
7
2
1
.0
0
0
.7
6
6
1
.5
2
0
.1
1
1
1
.3
3
0
.0
0
0
N
M
_
0
2
3
1
6
8
G
ri
n
a
G
lu
ta
m
at
e
re
ce
p
to
r,
io
n
o
tr
o
p
ic
,
N
-m
et
h
y
l
D
-a
sp
ar
ta
te
-a
ss
o
ci
at
ed
p
ro
te
in
1
(g
lu
ta
m
at
e
b
in
d
in
g
)
1
.0
7
0
.8
6
0
1
.0
3
0
.9
1
6
1
.1
3
0
.6
2
1
1.
78
0.
03
3
1.
87
0.
00
0
N
M
_
0
0
1
0
3
3
3
5
1
G
ri
n
3
a
G
lu
ta
m
at
e
re
ce
p
to
r
io
n
o
tr
o
p
ic
,
N
M
D
A
3
A
2
1
.1
7
0
.7
6
9
2
1
.4
6
0
.1
2
8
1
.0
3
0
.7
4
8
1
.1
5
0
.3
5
8
2
1
.1
0
0
.9
7
4
N
M
_
0
1
3
8
0
5
C
ld
n
5
C
la
u
d
in
5
2
2.
15
0.
00
0
2
1.
89
0.
00
0
2
1
.6
9
0
.0
5
7
2
1
.4
9
0
.1
1
8
2
1
.4
1
0
.0
0
0
N
M
_
0
1
6
6
7
5
C
ld
n
2
C
la
u
d
in
2
2
.2
1
0
.2
1
0
3.
21
0.
02
6
2
.4
9
0
.1
0
3
1
.8
6
0
.1
6
3
1
.3
0
0
.0
0
0
N
M
_
0
1
0
1
4
1
E
p
h
a7
E
p
h
re
ce
p
to
r
A
7
1
.3
1
0
.4
3
2
1.
69
0.
01
9
1
.2
0
0
.8
3
6
2.
17
0.
03
0
1.
54
0.
00
0
N
M
_
0
1
6
8
6
8
H
if
3
a
H
y
p
o
x
ia
in
d
u
ci
b
le
fa
ct
o
r
3
,
al
p
h
a
su
b
u
n
it
1
.4
5
0
.2
6
3
1
.6
6
0
.0
6
3
1
.7
5
0
.0
5
3
2.
96
0.
00
4
1.
63
0.
00
0
N
M
_
0
0
8
2
5
6
H
m
g
cs
2
3
-h
y
d
ro
x
y
-3
-m
et
h
y
lg
lu
-
ta
ry
l-
C
o
en
zy
m
e
A
sy
n
th
as
e
2
2
1
.0
6
0
.9
2
4
2
1.
58
0.
00
4
2
1
.0
9
0
.7
0
4
2
1
.0
0
0
.9
2
5
2
1.
61
0.
00
0
N
M
_
0
2
0
5
6
8
P
li
n
4
P
er
il
ip
in
4
2.
51
0.
00
0
2.
26
0.
00
0
1
.4
0
0
.1
3
9
2.
14
0.
00
6
1.
73
0.
00
0
N
M
_
0
0
9
1
5
3
S
em
a3
b
S
em
a
d
o
m
ai
n
,
im
m
u
n
o
g
lo
b
u
li
n
d
o
m
ai
n
(I
g
),
sh
o
rt
b
as
ic
d
o
m
ai
n
,
se
cr
et
ed
,
(s
em
ap
h
o
ri
n
)
3
B
1
.6
0
0
.3
7
2
1
.8
8
0
.1
3
4
1
.2
8
0
.4
9
5
1
.4
5
0
.2
6
0
1.
57
0.
00
0
N
M
_
0
0
9
1
5
4
S
em
a5
a
S
em
a
d
o
m
ai
n
,
se
v
en
th
ro
m
b
o
sp
o
n
d
in
re
p
ea
ts
(t
y
p
e
1
an
d
ty
p
e
1
-l
ik
e)
,
tr
an
s-
m
em
b
ra
n
e
d
o
m
ai
n
(T
M
)
an
d
sh
o
rt
cy
to
p
la
sm
ic
d
o
m
ai
n
,
(s
em
ap
h
o
ri
n
)
5
A
2
1
.2
3
0
.4
1
6
1.
51
0.
04
8
1
.0
2
0
.8
4
7
1.
91
0.
01
7
1.
50
0.
00
0
N
M
_
0
1
0
3
6
8
G
u
sb
G
lu
cu
ro
n
id
as
e,
b
et
a
1
.0
5
0
.9
2
9
1
.0
5
0
.8
9
4
1
.0
0
1
.0
0
0
1
.0
0
1
.0
0
0
1
.0
7
0
.8
7
2
V
al
u
es
th
at
m
ee
t
th
e
6
1
.5
-f
o
ld
ch
an
g
e
an
d
fa
ls
e-
d
is
co
v
er
y
ra
te
-
(F
D
R
)
P
-v
al
u
e
<
0
.0
5
cu
t-
o
ff
ar
e
in
b
ol
d
.
Environmental and Molecular Mutagenesis. DOI 10.1002/em
Transcriptional Investigation of BaPNeurotoxicity 9
observed in MutaTMMouse lung and liver (Fig. 3) [Halap-
panavar et al., 2011]. Closer inspection of the interpolated
values for the BaP-DNA adducts data from previous stud-
ies shows that there were 116.56 72.8 adducts per 108
nucleotides in the liver 24 h after the last BaP exposure
at the interpolated dose of 70 mg/kg bw per day, which
overlaps with the cerebellum adduct level of 64.26 17.6
adducts per 108 nucleotides at this dose from this study
(Fig. 3). Therefore, these differences in BaP-DNA adduct
levels between the cerebellum, liver and lung may be
considered relatively small.
Our data suggest that the transcriptional DNA damage
response is not as prevalent in the brain as in other tis-
sues. For example, IPA pathways relating to DNA dam-
age response and cell cycle alterations used in assessing
the carcinogenic MOA of BaP [Moffat et al., 2015] were
only marginally affected in the hippocampus. Overall, the
DNA damage response commonly associated with BaP
does not appear to be a significant driver of BaP-induced
neurotoxicity based on our data. Thus, our study does not
support that BaP-induced genotoxicity leading to neuronal
cell death is the most plausible MOA (reviewed in [Che-
pelev et al., 2015]). Nevertheless, additional studies are
required to fully support this conclusion, such as tran-
scriptional profiling of the hippocampus of wild type and
DNA repair-deficient mice following BaP treatment.
We set out to evaluate the evidence to support the
hypothesis that transcriptional perturbations of NMDARs
may be associated with impaired learning and memory
(MOA reviewed in [Chepelev et al., 2015]). Briefly, per-
meability to calcium confers NMDARs the ability to par-
ticipate in increasing synaptic signalling (i.e., long-term
potentiation), which is the current model for learning and
memory formation in the hippocampus. Transgenic rodent
models with hippocampus-specific alterations of NMDR
expression confirm the importance of this receptor in
learning and memory. For example, knock-out of NR1
expression in the murine CA1 hippocampal region com-
promises their performance in the Morris water maze test
[Shimizu et al., 2000], while forebrain-specific overex-
pression of NR2B in aged mice enhances their perform-
ance in five different memory tests compared to age-
matched wild type controls [Cao et al., 2007]. Thus,
NMDARs are ideal hypothetical candidates for involve-
ment in the neurotoxicity of BaP.
Given the established importance of NMDARs in learn-
ing and memory, and previous publications suggesting
that NDMARs may be perturbed following BaP exposure
[Brown et al., 2007; Grova et al., 2007; Grova et al.,
2008; Qiu et al., 2011; Cheng et al., 2013], we specifi-
cally investigated the response of NMDAR transcripts in
order to explore their potential role in the neurotoxic
effects of BaP. There have been five studies on the effects
of BaP on NMDAR in the hippocampus of adult mouse
or rat hippocampus, each of them reporting perturbed
expression of at least one of the three subunits Grin1,
Grin2a, or Grin2b (Table II). However, the published
results are inconsistent. Our results demonstrate measura-
ble increases in Grin2a by both RT-PCR and DNA
microarrays, in addition to increased expression of Grina,
another NMDAR (Table I). The direction of the noted
changes of Grin2a in the hippocampus of mice and rats
in response to BaP differs between studies (Table II) and
the differences could be sex-specific (i.e., three studies
support increases in adult males, but the single study on
BALB/c adult female mice shows decreased expression).
Alternatively, the noted difference could arise due to dif-
ferent timing between the last treatment and the necropsy.
Nonetheless, regardless of the direction of change, all five
published studies show altered expression of at least one
of the NMDAR genes in rodent hippocampus (Table II).
It is possible that altered expression of Grin1, Grin2a
and/or Grin2b may be sufficient to change the molecular
composition of NMDARs, thereby interfering with the
normal function of this type of glutamate receptor. There-
fore, our data confirm previous reports demonstrating
altered expression of NMDARs following BaP exposure,
supporting the potential involvement of NMDARs in
mediating BaP neurotoxicity.
It has been proposed that Grin2a is controlled by AHR
since Grin2a levels decline following AHR silencing, and
increase with AHR stimulation by 2,3,7,8-Tetrachlorodi-
benzodioxin (TCDD) in rat cortical neurons [Lin et al.,
2009]. Therefore, the Grin2a upregulation observed in
our study may be due to AHR activation by BaP. How-
ever, other classical targets of AHR-mediated transcrip-
tional changes, including Cyp1a1, Cyp1b1, and Nqo1,
were unaffected in the hippocampus following BaP
exposure as measured by RNA-seq, microarrays, and RT-
PCR. If both Cyp1a1 and Grin2a are indeed transcrip-
tional targets of AHR-mediated BaP-induced changes, the
lack of an effect on Cyp1a1 expression in the hippocam-
pus 24 hr after the last exposure is similar to hepatic, but
not pulmonary effects observed in MutaTMMouse 24 hr
after a 3-day repeat oral gavage to similar BaP doses (50
and 150 mg/kg bw per day, Supporting Information Fig.
2) [Moffat et al., 2015]. It is unlikely that the lack of a
BaP effect on the expression of Cyp1a1 24 hr after the
last exposure in the hippocampus and liver is due to
declining levels of BaP and its metabolites, since intraper-
itoneal injection of Wistar rats with radio-labeled BaP
showed a peak of radioactivity in the brain, lung, and kid-
ney 23 hr after administration [Das et al., 1985]. There-
fore, additional work is needed to determine whether
Grin2a and other NMDAR genes are under the transcrip-
tional control of AHR, for example, by exposing AHR
knock-out animals to BaP and conducting genomics and
neurobehavioral experiments.
The presence of BaP metabolites in the brain was
clearly indicated by the dose-related increases in the
Environmental and Molecular Mutagenesis. DOI 10.1002/em
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frequency of BaP-DNA adducts. Mono-hydroxylated
metabolites of BaP share strong structural similarity to the
classical estrogen receptor ligand 17-beta-estradiol (E2).
The mono-hydroxylated BaP metabolites 3-OH-BaP and 9-
OH-BaP, but not the parent compound, competitively bind
to recombinant human ER alpha and ER beta receptors in
vitro to strongly induce a beta-galactosidase reporter gene
in human MCF-7 cells [Fertuck et al., 2001]. Although we
have no evidence to support the presence of hydroxylated
BaP metabolites in the brain, the presence and dose-
dependent increase of 3-OH-BaP in whole rat brain follow-
ing single administration of 5, 50, or 100 mg BaP/kg bw
by intragastrical administration has been reported 12 hr
after administration [Liu et al., 2015]. Interestingly, that
work revealed about 20, 55, and 75-fold excess of 3-OH-
BaP over (1)-anti-BPDE at 5, 50, and 100 mg/kg doses;
the concentration of both metabolites was 456.26 56.4
and 24.36 1.3 at the 5-mg/kg dose, respectively [Liu
et al., 2015]. These results suggest the presence of mono-
hydroxylated BaP metabolites in the animals examined in
our study and the reported estrogenic properties of these
metabolites are consistent with robust activation of ESR1
predicted by our transcriptomic data. Indeed, ESR1 was
identified as the top upstream regulator (in an activation
state) in both the microarray and RNA-seq analysis. Fur-
thermore, of the 72 genes that are shared between this and
the most similar study identified using NextBio, 15 are
regulated by ESR1, again suggesting activation. These
results, as well as the existence of established AHR-ESR
cross-talk [Kummer et al., 2008], suggest the involvement
of these receptors in mediating BaP neurotoxicity and mer-
its further investigation.
According to an emerging concept, exposure to geno-
toxic compounds may cause both carcinogenicity and
neurotoxicity, depending upon the presence or absence of
active cell division [Kisby et al., 2011]. A previous study
[Hakura et al., 1998] used the MutaTMMouse model to
support this concept. Five days of exposure to 125 mg
BaP/kg bw per day led to high lacZ mutant frequencies
in tissues prone to BaP-induced carcinogenicity (e.g., for-
estomach, liver, lung) on the 14th day after the last BaP
treatment. However, increased mutant frequencies were
not observed in the brain, prompting the authors to sug-
gest the crucial role of rapid cell division in BaP carcino-
genicity. In the case of MAM, there is a disruption of
common signaling pathways in the colon and the brain
(i.e., the TGF-beta, Wnt, and MAPK pathways), leading
to either carcinogenicity or neurotoxicity, respectively
[Kisby et al., 2011]. Whether these pathways are also
shared between the tissues exhibiting BaP-mediated carci-
nogenicity and neurotoxicity is unknown. A comparison
of 24 hr post-exposure liver transcriptomic profiles in
response to 300 mg BaP/kg bw per day for three days
[Moffat et al., 2015] and the 24 hr post-exposure hippo-
campal gene expression in response to 70 mg BaP/kg bw
per day for three days (i.e., this study), indicates very lit-
tle effect (Fischer’s exact P-values of 1.0 for liver and
0.08 for hippocampus) on the Wnt/catenin signaling path-
way in these tissues; however, it is worth noting that
there were three (Ccnd1, Cdh1, and Wnt5b) and four
(Fzd4, Sfrp5, Wnt7a, and Wnt7b) genes affected from this
pathway in liver and hippocampus, respectively. Toxico-
genomic studies provide “snapshot” representations of
dynamic gene expression networks; thus, despite the lack
of support for the aforementioned hypothesis [Kisby
et al., 201] in our study, the effects of BaP on common
signaling pathways that would lead to either neurotoxicity
or cancer do merit further investigation.
TABLE II.The Effect of BaP on Gene Expression of NMDAR Subunits NR1 (Grin1) and NR2 (Grin2) in the Mouse and Rat
Hippocampus
Animals Exposure and duration NR1 NR2A NR2B References
Long Evans rat $, # Gestational exposure
(oral gavage of moth-
ers) at gestational
days 14-17; measured
at postnatal days 2, 5,
10, 15, 20
N. A. # # [Brown et al., 2007]
BALB/c mouse $, adult Intraperitoneal injection
for 10 days
" N. A. N. A. [Grova et al., 2007]
BALB/c mouse $, adult Intraperitoneal injection
for 10 days
" # (2 high doses) # [Grova et al., 2008]
Sprague-Dawley rat #, adult Intraperitoneal injection
for 98 days
N. A. " N. A. [Qiu et al., 2011]
Sprague-Dawley rat #, adult Intraperitoneal injection
for 45 days
" [Cheng et al., 2013]
MutaTMMouse #, adult Oral gavage for 3 days N. C. " N. C. [This study]
N. A., not available (not measured); N. C., no change.
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A meta-analysis of publicly available data revealed that
the gene expression pattern that is most similar to the one
we describe herein was found in the hippocampus of GLP
knock-out mice compared to wild type [Schaefer et al.,
2009]. Again, genes shared between the GLP knock-out
study and this study are indicative of ESR1 activation.
GLP is a histone-lysine N-methyltransferase; neuron-
specific, postnatal knock-out of GLP in mice leads to
transcriptional de-repression of many non-neuronal and
neuron progenitor genes in adult neurons, as well as com-
plex behavioral abnormalities [Schaefer et al., 2009]. For
example, in an elevated plus maze test that assesses
awareness of potential danger or anxiety by measuring
the degree to which the rodent avoids the open arm of
the maze, GLP knock-out mice showed an increased
number of entries into open arms, spent more time in
open arms, and had lower total arm entries [Schaefer
et al., 2009]. Very similar behavioral outcomes on the
elevated plus maze test were observed in adult mice
treated with BaP [Bouayed et al., 2012], suggesting that
animals with both genotypes had reduced awareness of
potential danger. Due to the different tests used in the
two studies, further direct comparison of the array of pos-
sible neurotoxic effects is impossible. However, many of
the aforementioned studies of BaP neurotoxicity in adult
rats and mice (e.g., [Grova et al., 2007; Cheng et al.,
2013; Qiu et al., 2011]) characterized the neurotoxic
effects of BaP administration as defects in learning, as
measured by deficits in spatial learning in the Morris
water maze test, which is comparable to impaired ability
of the GLD knock-out mice to remember negative experi-
ences in the fear conditioning paradigm [Schaefer et al.,
2009]. Due to the similarity of GLP knock-out-mediated
neurotoxicity and BaP-induced alterations in neurobeha-
vioral task performance related to learning and memory,
as well as similar effects on ESR1-mediated gene expres-
sion between the studies, the involvement of ESR1 in
BaP-induced neurotoxicity also warrants further
investigation.
BMD analysis revealed that three out of the 11 IPA
pathways in which Grin proteins are involved (Amyotro-
phic Lateral Sclerosis Signaling, Synaptic Long Term
Potentiation, and Huntington’s Disease Signaling) were
also among the 10 “most sensitive pathways” (i.e., those
with the lowest median BMDL values). The Synaptic
Long Term Potentiation pathway had the lowest median
BMDL (5.2 mg/kg bw per day) and is biologically rele-
vant based on the proposed role of NMADRs in the neu-
rotoxic MOA of BaP. Thus, we propose that this is the
most relevant pathway on which to derive a toxicogenom-
ics point of departure (POD) estimation for adult neuro-
toxicity following BaP exposure. This POD is in
consistent with PODs of 1.0, 3.7, and 7.4 mg/kg bw per
day that we determined using liver, lung, and forestomach
toxicogenomics profiles, respectively, for cancer risk
assessment [Moffat et al., 2015]. Therefore, the toxicoge-
nomics PODs for adult mouse neurotoxicity and carcino-
genicity are very similar. It remains to be determined
whether toxicogenomics PODs would be significantly
lower should exposures be conducted during critical
developmental stages.
In conclusion, our study provides experimental data
that support an NMDAR-mediated MOA for BaP-induced
hippocampal responses and concomitant neurotoxicity.
We identified a number of genes regulated by ESR1 that
are potentially important in mediating the neurotoxicity of
BaP and other PAHs other PAHs, as well as several neu-
rotoxic compounds and conditions leading to neurotoxic
outcomes (e.g., GLP knock-out in the mouse discussed
above). Although DNA adduct levels could not be meas-
ured in the hippocampus of the animals examined, our
hippocampal gene expression analysis, which employed
three different technologies, provides little support for
significant DNA damage in this tissue. However, these
results should be interpreted with caution and we empha-
size that further studies are needed to conclusively deter-
mine whether genotoxicity plays a role in the altered
learning and behavior observed following rodent BaP
exposures. The efficiency of DNA repair in the human
brain is age-dependent, such that age-dependent increases
in the extent of oxidative DNA damage appears to reduce
the expression of certain genes involved in learning,
memory, and neuronal survival [Lu et al., 2004]. There-
fore, it is conceivable that the timing of BaP exposure is
a crucial factor that determines whether BaP induces neu-
rotoxic effects, and moreover, the MOA by which the
effects are manifested (i.e., genotoxic vs. NMDAR-
dependent). Transcriptomics studies similar to this one in
DNA repair-deficient mice, in younger exposed animals,
and in animals examined at various times post-exposure
would provide additional evidence to assess the extent to
which BaP genotoxicity plays a role in its neurotoxicity
in developing and adult rodents. In addition, the extent to
which DNA damage-induced cytotoxicity during critical
periods of brain development (i.e., during periods of
extensive cellular proliferation) contributes to neurotoxic-
ity should be studied in detail.
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